Literature DB >> 7971707

Evaluation of solubilizers in the drug release testing of hydrophilic matrix extended-release tablets of felodipine.

B Abrahamsson1, D Johansson, A Torstensson, K Wingstrand.   

Abstract

The drug release of felodipine, a water-insoluble drug, was tested by using sodium lauryl sulphate (SLS), polyoxyethylene 20 sorbitan monooleate (Tween) or cetyltrimethylammonium bromide (CTAB) in the test medium as solubilizers. Three slightly different felodipine extended-release (ER) tablets 10 mg based on the gel matrix principle were evaluated under different solubilizer concentrations, agitation intensities and pH. These tablets were also tested in a bioavailability study together with an oral solution. All three solubilizers substantially enhanced the drug solubility and sink conditions were obtained. The choice of solubilizer affected the drug release rate. This is most probably due to physico-chemical interactions between the gel-forming agent and the solubilizers. All in vitro test conditions provided a good correlation (r2 = 0.94-0.97) to in vivo dissolution, as determined by moment analysis. However, a much steeper in vitro/in vivo relationship was obtained for SLS compared to Tween and CTAB reflecting an inferior discrimination between the tablets by use of this anionic solubilizer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7971707     DOI: 10.1023/a:1018920412020

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  7 in total

1.  Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.

Authors:  E Blychert; K Wingstrand; B Edgar; K Lidman
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

2.  Moment analysis in vivo and in vitro.

Authors:  H M von Hattingberg
Journal:  Methods Find Exp Clin Pharmacol       Date:  1984-10

3.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

4.  Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms.

Authors:  M Gibaldi; S Feldman
Journal:  J Pharm Sci       Date:  1967-10       Impact factor: 3.534

5.  Determination of felodipine in plasma by capillary gas chromatography with electron capture detection.

Authors:  M Ahnoff
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

Review 6.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

7.  In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants.

Authors:  V P Shah; J J Konecny; R L Everett; B McCullough; A C Noorizadeh; J P Skelly
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

  7 in total
  4 in total

1.  An investigation into the stabilization of diltiazem HCl release from matrices made from aged polyox powders.

Authors:  Saeed Shojaee; Kofi Asare-Addo; Waseem Kaialy; Ali Nokhodchi; Iain Cumming
Journal:  AAPS PharmSciTech       Date:  2013-07-31       Impact factor: 3.246

2.  Preparation and in vitro/in vivo evaluation of felodipine nanosuspension.

Authors:  Bhanu P Sahu; Malay K Das
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-11-07       Impact factor: 2.441

3.  Quantification of swelling and erosion in the controlled release of a poorly water-soluble drug using synchrotron X-ray computed microtomography.

Authors:  Xianzhen Yin; Haiyan Li; Zhen Guo; Li Wu; Fangwei Chen; Marcel de Matas; Qun Shao; Tiqiao Xiao; Peter York; You He; Jiwen Zhang
Journal:  AAPS J       Date:  2013-07-16       Impact factor: 4.009

4.  A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.

Authors:  Laura Maria Fuhr; Fatima Zahra Marok; Maximilian Mees; Felix Mahfoud; Dominik Selzer; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.